Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Varun Sundaram Added: 3 days ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more
Author(s): Scott Harris Added: 10 months ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the… View more
Author(s): Phyo Htoo Added: 8 months ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design… View more
Author(s): Barry Borlaug Added: 3 months ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more
Author(s): Samuel S Engel Added: 1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more